D. van der Heijde
About
D. van der Heijde is a scholar working on Rheumatology, Immunology and Pathology and Forensic Medicine.
According to data from OpenAlex, D. van der Heijde has authored 72 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Rheumatology, 16 papers in Immunology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in D. van der Heijde's work include Rheumatoid Arthritis Research and Therapies (49 papers), Spondyloarthritis Studies and Treatments (41 papers) and Psoriasis: Treatment and Pathogenesis (13 papers). D. van der Heijde is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (49 papers), Spondyloarthritis Studies and Treatments (41 papers) and Psoriasis: Treatment and Pathogenesis (13 papers). D. van der Heijde collaborates with scholars based in Netherlands, United States and Canada. D. van der Heijde's co-authors include Joachim Sieper, Jürgen Braun, Philippe Ravaud, Maxime Dougados, G H Kingsley, Jürgen Braun, Walter P. Maksymowych, S. Paternotte, Rubén Burgos‐Vargas and Claire Bombardier and has published in prestigious journals such as Annals of the Rheumatic Diseases, Osteoarthritis and Cartilage and Lara D. Veeken.
In The Last Decade
D. van der Heijde
69 papers receiving 1.6k citations
Hit Papers
Peers
D. van der Heijde
Adeline Ruyssen‐Witrand France
Xavier Juanola Spain
Gurjit S. Kaeley United States
D. van der Heijde Netherlands
C. Stolwijk Netherlands
Emmanuelle Dernis France
O. Mejjad France
Rafael Valle‐Oñate Colombia
F. Navarro-Sarabia Spain
Euthalia Roussou United Kingdom
Citations per year, relative to D. van der Heijde D. van der Heijde (= 1×)
peers
Adeline Ruyssen‐Witrand
Countries citing papers authored by D. van der Heijde
Since
Specialization
Citations
This map shows the geographic impact of D. van der Heijde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. van der Heijde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. van der Heijde more than expected).
Fields of papers citing papers by D. van der Heijde
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by D. van der Heijde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. van der Heijde. The network helps show where D. van der Heijde may publish in the future.
Co-authorship network of co-authors of D. van der Heijde
This figure shows the co-authorship network connecting the top 25 collaborators of D. van der Heijde. A scholar is included among the top collaborators of D. van der Heijde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. van der Heijde. D. van der Heijde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Mease, Philip J., A.B. Gottlieb, Iain B. McInnes, et al.. (2022). POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 81. 831–832.
2.
Heijde, D. van der, Dafna D. Gladman, Oliver FitzGerald, et al.. (2017). Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels : Results from a Phase 3 Clinical Study. Arthritis & Rheumatism. 69.
3.
Heijde, D. van der, J. Wollenhaupt, Stanley Cohen, et al.. (2017). Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years. Arthritis & Rheumatism. 69.
4.
Heijde, D. van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2016). LONG-TERM EFFICACY AND TOLERABILITY OF GOLIMUMAB IN ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS : RESULTS OF THE OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND STUDY. Clinical and Experimental Rheumatology. 34(4). 752–752.
5.
Barnabé, Cheryl, Yangbo Sun, Gilles Boire, et al.. (2015). Sociodemographic and Health Status Characteristics Explain Five Clinical Outcome and Radiographic Trajectories in Early Rheumatoid Arthritis: Data from the CATCH Cohort. The Journal of Rheumatology. 42(7). 1277–1277.
6.
Hooge, Manouk de, J Pialat, A. Feydy, et al.. (2014). Is It Worth to Include MRI of the Spine in the ASAS Classification Criteria for Axial Spondyloarthritis. Arthritis & Rheumatism. 66.
7.
Abawi, Ozair, Ronald van den Berg, D. van der Heijde, & F. van Gaalen. (2014). EVALUATION OF REFERRAL MODELS FOR AXIAL SPONDYLOARTHRITIS IN PRIMARY CARE IN THE SPONDYLOARTHRITIS CAUGHT EARLY COHORT. Clinical and Experimental Rheumatology. 32(5). 426–426.
8.
Bek, Stephan, Arndt Brachat, J. Sieper, et al.. (2012). Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B). Data Archiving and Networked Services (DANS). 64(10).
9.
Baraliakos, Xenofon, Jerry Braun, Didier Laurent, et al.. (2012). Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.. Data Archiving and Networked Services (DANS). 64(10).
10.
Kwok, Wing‐Yee, Marion C Kortekaas, M. Reijnierse, et al.. (2011). 45 MRI IN HAND OSTEOARTHRITIS: VALIDATION OF THE OSLO HAND OSTEOARTHRITIS MRI-SCORING METHOD AND ASSOCIATION WITH PAIN. Osteoarthritis and Cartilage. 19. S26–S27.
11.
Baraliakos, Xenofon, Jerry Braun, Didier Laurent, et al.. (2011). Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging. Data Archiving and Networked Services (DANS). 63(10).
12.
Lukas, Cédric, et al.. (2011). Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des Polyarthrites IndifféRenciées récentes (Study and Followup of Early Undifferentiate. Arthritis & Rheumatism. 63(7). 1804–1811.
13.
Paternotte, S., Jürgen Braun, Rubén Burgos‐Vargas, et al.. (2010). ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Annals of the Rheumatic Diseases. 70(2). 249–251.
14.
Heijde, D. van der, et al.. (2010). Developing and validating an index for measuring health in patients with ankylosing spondylitis. Lara D. Veeken. 50(5). 894–898.
15.
Braun, Jürgen, Xenofon Baraliakos, Joachim Listing, et al.. (2007). Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti–tumor necrosis factor α agents. Arthritis Care & Research. 57(4). 639–647.
16.
Pham, Thao, Robert Landewé, S van der Linden, et al.. (2006). An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Annals of the Rheumatic Diseases. 65(12). 1620–1625.
17.
Vosse, Debby, P. Geusens, D. van der Heijde, et al.. (2004). Ankylosing spondylitis and the risk of fracture.. Document Server@UHasselt (UHasselt). 50.
18.
Tubach, Florence, Gabriel Baron, Philippe Ravaud, et al.. (2003). Evaluation of clinically relevant changes and states in symptomatic outcome variables in osteoarthritis. Queensland's institutional digital repository (The University of Queensland). 48(9). 276–276.
19.
Strand, Vibeke, R. B. M. Landewé, & D. van der Heijde. (2002). Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. Annals of the Rheumatic Diseases. 61. ii64–ii66.
20.
Braun, Jürgen, G H Kingsley, D. van der Heijde, & Joachim Sieper. (2000). On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999.. PubMed. 27(9). 2185–92.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Adeline Ruyssen‐Witrand Breakdown of academic impact, for papers by Xavier Juanola Breakdown of academic impact, for papers by Gurjit S. Kaeley Breakdown of academic impact, for papers by D. van der Heijde Breakdown of academic impact, for papers by C. Stolwijk Breakdown of academic impact, for papers by Emmanuelle Dernis Breakdown of academic impact, for papers by O. Mejjad Breakdown of academic impact, for papers by Rafael Valle‐Oñate Breakdown of academic impact, for papers by F. Navarro-Sarabia Breakdown of academic impact, for papers by Euthalia Roussou